News und Analysen
![These 5 growth stocks are now in buy ranges: https://www.marketbeat.com/logos/articles/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3NXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d1449d87eff5ec63be63f510265fc5a83e7777d3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg?locale=de)
These 5 growth stocks are now in buy ranges
Chart patterns and consolidations are worth watching, as they provide actionable guidance for making a purchase.
With the recent uptrend in large-cap stocks, as reflected by the performance of
![These 5 growth stocks are now in buy ranges: https://www.marketbeat.com/logos/articles/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3NXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d1449d87eff5ec63be63f510265fc5a83e7777d3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg?locale=de)
These 5 growth stocks are now in buy ranges
Chart patterns and consolidations are worth watching, as they provide actionable guidance for making a purchase.
With the recent uptrend in large-cap stocks, as reflected by the performance of
![Verizon and AT&T: One is a high-yield value, the other a trap: https://www.marketbeat.com/logos/articles/med_20240124114037_chart-vz-att-1242023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzBXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3b7e0ef167936d206ac98ef741fbb5a5b80b8750/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124114037_chart-vz-att-1242023ver001.png?locale=de)
Verizon and AT&T: One is a high-yield value, the other a trap
Verizon Communications Inc. (NYSE: VZ) and AT&T Inc. (NYSE: T) have presented value and yield to investors for years.
However, they failed to sustain interest in their stocks, creating a drag on
![Verizon and AT&T: One is a high-yield value, the other a trap: https://www.marketbeat.com/logos/articles/med_20240124114037_chart-vz-att-1242023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzBXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3b7e0ef167936d206ac98ef741fbb5a5b80b8750/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124114037_chart-vz-att-1242023ver001.png?locale=de)
Verizon and AT&T: One is a high-yield value, the other a trap
Verizon Communications Inc. (NYSE: VZ) and AT&T Inc. (NYSE: T) have presented value and yield to investors for years.
However, they failed to sustain interest in their stocks, creating a drag on
![These 5 growth stocks are now in buy ranges: https://www.marketbeat.com/logos/articles/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3NXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d1449d87eff5ec63be63f510265fc5a83e7777d3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg?locale=de)
These 5 growth stocks are now in buy ranges
Chart patterns and consolidations are worth watching, as they provide actionable guidance for making a purchase.
With the recent uptrend in large-cap stocks, as reflected by the performance of
![Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Massives Kaufsignal. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73376/AC-250124.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2NXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--51e8f43bc76027b0a55cfc091add53df0fbcc148/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-250124.001.png?locale=de)
Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Massives Kaufsignal. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Neuer 224% Biotech Hot Stock nach 134.452%
25.01.24 08:03
London (www.aktiencheck.de , Anzeige)
![Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Massives Kaufsignal. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73376/AC-250124.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2NXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--51e8f43bc76027b0a55cfc091add53df0fbcc148/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-250124.001.png?locale=de)
Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Massives Kaufsignal. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Neuer 224% Biotech Hot Stock nach 134.452%
25.01.24 08:03
London (www.aktiencheck.de , Anzeige)
![Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Massives Kaufsignal. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73376/AC-250124.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2NXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--51e8f43bc76027b0a55cfc091add53df0fbcc148/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-250124.001.png?locale=de)
Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Massives Kaufsignal. Neuer 224% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Durchbruch in Krebstherapie - Institutionelle Investoren vor Einstieg. Neuer 224% Biotech Hot Stock nach 134.452%
25.01.24 08:03
London (www.aktiencheck.de , Anzeige)
![Food fight! Which grocery store stocks will win in 2024?: https://www.marketbeat.com/logos/articles/med_20240124122319_food-fight-which-grocery-store-stocks-will-win-in.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7df2b5afc964d3530a54c72d23ac9340c2bf41dc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124122319_food-fight-which-grocery-store-stocks-will-win-in.jpg?locale=de)
Food fight! Which grocery store stocks will win in 2024?
Food distributors and retailers are living up to their reputation as the best consumer staples industry to own.
Up 2.1% year-to-date, the group has a sizable early lead over its roughly flat sec
![Intuitive Surgical’s post-earnings dip is a healthy time to buy: https://www.marketbeat.com/logos/articles/med_20240124145004_chart-isrg-1242024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3dXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--74b2b11532bc44928a7d138b53c2a9d47f4b17d2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124145004_chart-isrg-1242024ver001.png?locale=de)
Intuitive Surgical’s post-earnings dip is a healthy time to buy
Intuitive Surgical (NASDAQ: ISRG) share prices surged following the Q4 release but failed to hold the gain, creating an ugly candle capping a strong rally. The market may move lower from here, but
![Intuitive Surgical’s post-earnings dip is a healthy time to buy: https://www.marketbeat.com/logos/articles/med_20240124145004_chart-isrg-1242024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3dXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--74b2b11532bc44928a7d138b53c2a9d47f4b17d2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124145004_chart-isrg-1242024ver001.png?locale=de)
Intuitive Surgical’s post-earnings dip is a healthy time to buy
Intuitive Surgical (NASDAQ: ISRG) share prices surged following the Q4 release but failed to hold the gain, creating an ugly candle capping a strong rally. The market may move lower from here, but
![5 top healthcare stocks for earnings growth in 2024: https://www.marketbeat.com/logos/articles/med_20240124120518_5-top-healthcare-stocks-for-earnings-growth-in-202.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzRXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--603b6f3363f5b803bb05f2ff2c902c3d9e326b9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124120518_5-top-healthcare-stocks-for-earnings-growth-in-202.jpg?locale=de)
5 top healthcare stocks for earnings growth in 2024
While the healthcare sector delivered lackluster profit growth in 2023, it should change this year.
Sector components forecast to show the biggest earnings year-over-year earnings improvement
![Why Apple’s about to smash through $200 and continue: https://www.marketbeat.com/logos/articles/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFVXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1727773504930f1490f188dd10e1f0c641431dcc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg?locale=de)
Why Apple’s about to smash through $200 and continue
Microsoft Corporation (NASDAQ: MSFT) recently overtook Apple Inc. (NASDAQ: AAPL) as the world's most valuable company while also setting its all-time high; expectations are high for Apple to make
![Why Apple’s about to smash through $200 and continue: https://www.marketbeat.com/logos/articles/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFVXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1727773504930f1490f188dd10e1f0c641431dcc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg?locale=de)
Why Apple’s about to smash through $200 and continue
Microsoft Corporation (NASDAQ: MSFT) recently overtook Apple Inc. (NASDAQ: AAPL) as the world's most valuable company while also setting its all-time high; expectations are high for Apple to make
![Why Apple’s about to smash through $200 and continue: https://www.marketbeat.com/logos/articles/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFVXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1727773504930f1490f188dd10e1f0c641431dcc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg?locale=de)
Why Apple’s about to smash through $200 and continue
Microsoft Corporation (NASDAQ: MSFT) recently overtook Apple Inc. (NASDAQ: AAPL) as the world's most valuable company while also setting its all-time high; expectations are high for Apple to make
![Why Apple’s about to smash through $200 and continue: https://www.marketbeat.com/logos/articles/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFVXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1727773504930f1490f188dd10e1f0c641431dcc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg?locale=de)
Why Apple’s about to smash through $200 and continue
Microsoft Corporation (NASDAQ: MSFT) recently overtook Apple Inc. (NASDAQ: AAPL) as the world's most valuable company while also setting its all-time high; expectations are high for Apple to make
![Will leverage and pricing power drive Netflix to a record high?: https://www.marketbeat.com/logos/articles/med_20240124071952_chart-nflx-1242024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0FXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bd153e85e3bae974925aec1768a1450ad12c1c1f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124071952_chart-nflx-1242024ver001.png?locale=de)
Will leverage and pricing power drive Netflix to a record high?
The Netflix Inc. (NASDAQ: NFLX) narrative is not without risk. The company struggled with growth following the COVID-19 bubble, but those days are behind. The story today is leverage, driven by
![Will leverage and pricing power drive Netflix to a record high?: https://www.marketbeat.com/logos/articles/med_20240124071952_chart-nflx-1242024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0FXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bd153e85e3bae974925aec1768a1450ad12c1c1f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124071952_chart-nflx-1242024ver001.png?locale=de)
Will leverage and pricing power drive Netflix to a record high?
The Netflix Inc. (NASDAQ: NFLX) narrative is not without risk. The company struggled with growth following the COVID-19 bubble, but those days are behind. The story today is leverage, driven by
![Will leverage and pricing power drive Netflix to a record high?: https://www.marketbeat.com/logos/articles/med_20240124071952_chart-nflx-1242024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0FXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bd153e85e3bae974925aec1768a1450ad12c1c1f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124071952_chart-nflx-1242024ver001.png?locale=de)
Will leverage and pricing power drive Netflix to a record high?
The Netflix Inc. (NASDAQ: NFLX) narrative is not without risk. The company struggled with growth following the COVID-19 bubble, but those days are behind. The story today is leverage, driven by
![Is it a logical time to buy Logitech?: https://www.marketbeat.com/logos/articles/med_20240124083605_chart-logi-1242024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--36dbd4d274ab0c7ca005cf0fafec9c6618aa5d4d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124083605_chart-logi-1242024ver001.png?locale=de)
Is it a logical time to buy Logitech?
Shares of Logitech International S.A. (NASDAQ: LOGI) fell sharply despite a solid earnings report and improved guidance. The move took share prices to a two-month low, setting up an attractive
![3 just-upgraded energy stocks to put on your radar: https://www.marketbeat.com/logos/articles/med_20240124085415_3-just-upgraded-energy-stocks-to-put-on-your-radar.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2dWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--820aaebefe179d666921b4f292cdbdb85b20bf67/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124085415_3-just-upgraded-energy-stocks-to-put-on-your-radar.jpg?locale=de)
3 just-upgraded energy stocks to put on your radar
Last night saw the S&P 500 index close at a fresh all-time high. It's a remarkable achievement that didn't look as likely as recently as October. But since the prospect of a rate cut became quite
![3 just-upgraded energy stocks to put on your radar: https://www.marketbeat.com/logos/articles/med_20240124085415_3-just-upgraded-energy-stocks-to-put-on-your-radar.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2dWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--820aaebefe179d666921b4f292cdbdb85b20bf67/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240124085415_3-just-upgraded-energy-stocks-to-put-on-your-radar.jpg?locale=de)
3 just-upgraded energy stocks to put on your radar
Last night saw the S&P 500 index close at a fresh all-time high. It's a remarkable achievement that didn't look as likely as recently as October. But since the prospect of a rate cut became quite
![Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73356/Aktiencheck240124_01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzRWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfc408a5357fd5f86d3ba9f42b583e708352ada7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck240124_01.001.png?locale=de)
Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Großinvestoren begeistert von innovativer Krebstherapie. Neuer 199% Biotech Aktientip nach 15.973% mit BioNTech
24.01.24
London (www.aktiencheck.de, Anzeige)
Link
![Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73356/Aktiencheck240124_01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzRWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfc408a5357fd5f86d3ba9f42b583e708352ada7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck240124_01.001.png?locale=de)
Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Großinvestoren begeistert von innovativer Krebstherapie. Neuer 199% Biotech Aktientip nach 15.973% mit BioNTech
24.01.24
London (www.aktiencheck.de, Anzeige)
Link
![Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73356/Aktiencheck240124_01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzRWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfc408a5357fd5f86d3ba9f42b583e708352ada7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck240124_01.001.png?locale=de)
Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Großinvestoren begeistert von innovativer Krebstherapie. Neuer 199% Biotech Aktientip nach 15.973% mit BioNTech
24.01.24
London (www.aktiencheck.de, Anzeige)
Link